Cite
METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor.
MLA
Chen, Xin, et al. “METTL3 Inhibitor Suppresses the Progression of Prostate Cancer via IGFBP3/AKT Pathway and Synergizes with PARP Inhibitor.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 179, Sept. 2024, p. 117366. EBSCOhost, https://doi.org/10.1016/j.biopha.2024.117366.
APA
Chen, X., Wang, M., Wang, H., Yang, J., Li, X., Zhang, R., Ding, X., Hou, H., Zhou, J., & Wu, M. (2024). METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 179, 117366. https://doi.org/10.1016/j.biopha.2024.117366
Chicago
Chen, Xin, Miaomiao Wang, Haoran Wang, Jingxin Yang, Xiaoxin Li, Rongyu Zhang, Xin Ding, Huimin Hou, Jinming Zhou, and Meng Wu. 2024. “METTL3 Inhibitor Suppresses the Progression of Prostate Cancer via IGFBP3/AKT Pathway and Synergizes with PARP Inhibitor.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 179 (September): 117366. doi:10.1016/j.biopha.2024.117366.